Figure S1 Mean incremental net monetary benefit (iNMB) for tapering csDMARDs minus tapering TNF-inhibitors first. Results are plotted against different levels of willingness to pay (WTP) per quality adjusted life year (QALY), and with 95% confidence intervals. The iNMB was calculated as the incremental benefit times different levels of WTP, minus the incremental costs. csDMARDs: conventional synthetic DMARDs; iNMB: incremental net monetary benefit; QALY: quality adjusted life year; WTP: willingness to pay.